Rovida Advisors Inc. bought a new position in Allergan PLC. (NYSE:AGN) in the second quarter, according to its most recent disclosure with the SEC. The firm bought 152,900 shares of the company’s stock, valued at approximately $37,168,000. Allergan PLC. comprises approximately 5.1% of Rovida Advisors Inc.’s portfolio, making the stock its 10th biggest position.
Several other institutional investors and hedge funds also recently modified their holdings of AGN. Veritas Asset Management LLP acquired a new stake in shares of Allergan PLC. in the 1st quarter worth $761,339,000. Iridian Asset Management LLC CT increased its stake in shares of Allergan PLC. by 141.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 1,283,833 shares of the company’s stock worth $306,733,000 after acquiring an additional 751,848 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Allergan PLC. in the 1st quarter worth $124,255,000. Blue Ridge Capital L.L.C. increased its stake in shares of Allergan PLC. by 24.1% in the 1st quarter. Blue Ridge Capital L.L.C. now owns 1,909,900 shares of the company’s stock worth $456,313,000 after acquiring an additional 370,400 shares during the last quarter. Finally, Harbour Capital Advisors LLC increased its stake in shares of Allergan PLC. by 21,412.3% in the 2nd quarter. Harbour Capital Advisors LLC now owns 345,917 shares of the company’s stock worth $1,423,000 after acquiring an additional 344,309 shares during the last quarter. 82.02% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: This report was posted by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark law. The legal version of this report can be viewed at https://weekherald.com/2017/09/19/rovida-advisors-inc-takes-position-in-allergan-plc-agn.html.
Allergan PLC. (AGN) opened at 221.54 on Tuesday. The firm has a 50-day moving average price of $230.85 and a 200 day moving average price of $236.29. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The firm has a market capitalization of $74.06 billion, a P/E ratio of 6.75 and a beta of 1.18.
Allergan PLC. (NYSE:AGN) last announced its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion during the quarter, compared to analyst estimates of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s revenue was up 8.8% on a year-over-year basis. During the same period in the prior year, the firm posted $3.35 earnings per share. Analysts forecast that Allergan PLC. will post $16.25 EPS for the current year.
The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Shareholders of record on Friday, August 18th were paid a dividend of $0.70 per share. The ex-dividend date was Wednesday, August 16th. This represents a $2.80 annualized dividend and a yield of 1.26%. Allergan PLC.’s dividend payout ratio is presently 9.95%.
A number of analysts have issued reports on the company. Vetr raised Allergan PLC. from a “sell” rating to a “hold” rating and set a $242.88 target price for the company in a research note on Monday, June 26th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $280.00 target price (up from $270.00) on shares of Allergan PLC. in a research note on Wednesday, August 9th. UBS AG reaffirmed an “outperform” rating and issued a $275.00 target price on shares of Allergan PLC. in a research note on Wednesday, August 9th. Royal Bank Of Canada set a $284.00 target price on Allergan PLC. and gave the stock a “buy” rating in a research note on Sunday, July 16th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and issued a $273.00 target price (up from $265.00) on shares of Allergan PLC. in a research note on Monday, July 17th. One research analyst has rated the stock with a sell rating, seven have given a hold rating and fifteen have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $274.69.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.